Fig. 1From: Azacitidine front-line in 339 patients with myelodysplastic syndromes and acute myeloid leukaemia: comparison of French-American-British and World Health Organization classificationsOverall survival of MDS and AML patients treated with azacitidine front-line within the AAR. a Patients classified according to WHO criteria. b Patients with MRF classified according to WHO criteria. c Patients classified according to FAB criteriaBack to article page